TG Therapeutics reports mixed Q3 results, provides FY outlook
by
Contributor since / Followers
Contributor since / Followers
2 months ago
- TG Therapeutics press release (NASDAQ:TGTX): Q3 GAAP EPS of $0.02 misses by $0.01.
- Revenue of $83.88M (-49.4% Y/Y) beats by $2.18M.
- Cash, cash equivalents and investment securities were $341.0 million as of September 30, 2024.
- Raising BRIUMVI U.S. net product revenue target to $300 to $305 million for the full year 2024 (prior guidance of $290 to $300 million for full year 2024) FY revenue consensus of $327.76M.